Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Rajkumar, S V, Gupta, V, Fonseca, R, Dispenzieri, A, Gonsalves, W I, Larson, D, Ketterling, R P, Lust, J A, Kyle, R A, Kumar, S K·2013·Leukemia
DOI 10.1038/leu.2013.86

Cited by (238)

Items 201–238 of 238

  1. Therapeutic Advances in the Management of Smoldering Myeloma
    Rafiullah Khan, Umar Zahid, Vidya Sagar Kollu, Nusrat Jahan, Ali McBride, Guido J. K. Tricot, Faiz Anwer · 2019 · American Journal of Therapeutics
  2. Mielomas pacientu bioķīmisko marķieru un morfoloģisko rādītāju prognostiskās nozīmes analīze kaulu slimības attīstībā. Promocijas darba kopsavilkums
    Daiga Auziņa · 2021
  3. Analysis of Prognostic Significance of Biochemical Markers and Morphological Parameters in the Development of Bone Disease in Myeloma Patients. Summary of the Doctoral Thesis
    Daiga Auziņa · 2021
  4. Myeloma and Leukemia
    Sameh Nassar, Gregory Peter Kaufman, Ahmed Taher, John E. Madewell, Bilal Mujtaba · 2022 · Elsevier eBooks
  5. Smoldering Multiple Myeloma
    María‐Victoria Mateos, Jesús F. San Miguel · 2017 · Springer eBooks
  6. Μελέτη της σχέσης της οδού των νευροπεπτιδίων με την οδό ουβικουϊτίνης – πρωτεασώματος στο πολλαπλό μυέλωμα
    Μαρία Βαΐου · 2016
  7. Mielomas pacientu bioķīmisko marķieru un morfoloģisko rādītāju prognostiskās nozīmes analīze kaulu slimības attīstībā. Promocijas darbs
    Daiga Auziņa · 2021
  8. Plasma Cell Neoplasms
    2017 · CRC Press eBooks
  9. Monoclonal gammopathy of unknown significance: Implications of Indian baseline data
    Kaveri Joshi, Suvir Singh · 2022 · The National Medical Journal of India
  10. Diagnostic Applications of Nuclear Medicine: Multiple Myeloma
    Gayanè Aghakhanyan, Martina Sollini, Sara Galimberti, Roberta Zanca, Roberto Boni, Enrica Esposito, Francesco Bartoli, Paola Anna Erba · 2022 · Springer eBooks
  11. Updates on Multiple Myeloma: What’s New in Risk Stratification, Treatment, and Prognosis
    Enas Yahya Mutahar · 2022 · IntechOpen eBooks
  12. Evaluación de estrategias inmunes para el control del mieloma múltiple a largo plazo
    Julio Dávila Valls · 2022 · Gredos (University of Salamanca)
  13. Diagnostic Applications of Nuclear Medicine: Multiple Myeloma
    Gayanè Aghakhanyan, Martina Sollini, Sara Galimberti, Roberta Zanca, Roberto Boni, Enrica Esposito, Francesco Bartoli, Paola Anna Erba · 2022 · Springer eBooks
  14. Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
    Rosalinda Termini, David Žihala, Evangelos Terpos, Albert Pérez-Montaña, Tomáš Jelı́nek, Marc Steffen Raab, Niels Weinhold, Elias Karl Mai, Anna Luise Grab, Jill Corre et al. · 2023
  15. Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
    Rosalinda Termini, David Žihala, Evangelos Terpos, Albert Pérez-Montaña, Tomáš Jelı́nek, Marc Steffen Raab, Niels Weinhold, Elias Karl Mai, Anna Luise Grab, Jill Corre et al. · 2023
  16. EXABS-121-MM MGUS/SMM: Incidence, Evaluation and Follow-up
    Timothy Martin Schmidt, Natalie S. Callander · 2023 · Clinical Lymphoma Myeloma & Leukemia
  17. Early intervention for high risk smoldering multiple myeloma (SMM)
    Po‐Huang Chen, Hong‐Jie Jhou, Ching‐Liang Ho, Hai-Lun Huang, Cho‐Hao Lee · 2023 · Cochrane Database of Systematic Reviews
  18. Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma
    Amelie Boquoi · 2023 · Journal of Blood Disorders
  19. Introduction to Multiple Myeloma and Multiple Myeloma Bone Disease
    Naseem Esteghamat, Mehrdad Abedi · 2024 · Springer eBooks
  20. De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma
    Shumin Chen, Lu Gao, Lin Feng, Zheng Wang, Ye Li, Qing Liu, Wenjie Song, Shu Kong, Yang Liu, Jin Lu et al. · 2025 · Frontiers in Medicine
  21. Risk factors of Asymptomatic (Smoldering) Multiple Myeloma
    Kateřina Machálková, Vladimír Maisnar · 2014 · Klinická biochemie a metabolismus
  22. Plasma cell disorders
    Caitlin L. Costello, Rafaël Fonseca · 2022
  23. Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis
    Poy P. Theprungsirikul, Rong Wang, Ishfaq Ahmad, Natalia Neparidze, Xiaomei Ma, Su‐Hsin Chang, Shi‐Yi Wang · 2025 · Clinical Lymphoma Myeloma & Leukemia
  24. Plasma cell disorders: monoclonal gammopathy of undetermined significance and multiple myeloma
    Caitlin L. Costello · 2025
  25. c-MAF protein expression in multiple myeloma
    M. V. Solov’eva, M. V. Solov’ev, M. V. Melnikova, A. M. Kovrigina, T. N. Obukhova, L. P. Mendeleeva · 2025 · Oncohematology
  26. Integration of autophagy-related genes and immune dysregulation reveals a prognostic landscape in multiple myeloma
    Yibo Xia, Dong Zheng, Xinyi Zhang, Shuxia Zhu, Enqing Lan, Hansen Ying, Zixing Chen, Bingxin Zhang, Shujuan Zhou, Yu Zhang et al. · 2025 · Frontiers in Oncology
  27. Three-Dimensional Organization of Telomeres: An Emerging Prognostic Biomarker in Multiple Myeloma
    Yulia Shifrin, Sabine Mai · 2025 · Cells
  28. Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma
    Atsushi Uehara, Kentaro Narita, Fuminari Fujii, Hajime Sakuma, Mitsuaki Oura, Masanori Toho, Daisuke Ikeda, Rikako Tabata, Masami Takeuchi, Kosei Matsue · 2025 · International Journal of Hematology
  29. Navigating the evolving management of smoldering multiple myeloma
    Mohammad Bakri Hammami, Rafael Renatino Canevarolo, Ariosto Siqueira Silva, Melissa Alsina, Nagi B. Kumar, Rachid Baz, Kenneth H. Shain · 2026 · HemaSphere
  30. Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes
    Gil Fridberg, Inbar Cohen, Renana Robinson, Iuliana Vaxman, Tamir Shragai, Svetlana Trestman, Tomer Ziv‐Baran, Natan Melamed, Pia Raanani, Irit Mazza Avivi et al. · 2026 · Cancers
  31. Apport de l’imagerie fonctionnelle par TEP dans la prise en charge diagnostique et thérapeutique du myélome multiple et comparaison à l’IRM de diffusion
    Charles Mesguich · 2020 · theses.fr (ABES)
  32. The genetic architecture of plasma cell disorders
    Eileen Mary Boyle · 2020 · theses.fr (ABES)
  33. Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
    Omar Nadeem, Michelle P. Aranha, Robert Allyn Redd, Michael Zach Koontz, J V Matous, Andrew Jenho Yee, Jeffrey A. Zonder, Andrew Daniel Kin, Sophie Magidson, Elizabeth D. Lightbody et al. · 2026 · Nature Communications
  34. Dissecting the role of long non-coding RNA in multiple myeloma
    Simone Zocchi · 2024 · theses.fr (ABES)
  35. The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility
    Nicholas McCaul, Richard J. Bingham, Andrew D. Blann · 2026 · British Journal of Biomedical Science
  36. Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy
    Kirti Arora, Lara Soueid, Louis Williams, Jahanvi Grover, Diana Basali, Jack Khouri, Yuvraj Kaushal, Sandra Mazzoni, Rockey Dahiya, Beth M Faiman et al. · 2026 · Cancers
  37. Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma?
    Bartosz Puła, Wiktoria Ryżewska, Artur Handziuk, Agata Tyczyńska, Tadeusz Kubicki · 2026 · Expert Review of Hematology
  38. Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
    S. Vincent Rajkumar · 2026 · American Journal of Hematology